CN107683283B - Bace1抑制剂 - Google Patents

Bace1抑制剂 Download PDF

Info

Publication number
CN107683283B
CN107683283B CN201680031828.0A CN201680031828A CN107683283B CN 107683283 B CN107683283 B CN 107683283B CN 201680031828 A CN201680031828 A CN 201680031828A CN 107683283 B CN107683283 B CN 107683283B
Authority
CN
China
Prior art keywords
fluorophenyl
thiazin
trimethyl
oxo
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680031828.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107683283A (zh
Inventor
比约恩·巴特尔斯
科西莫·多伦特
沃尔夫冈·古帕
沃尔夫冈·哈普
乌尔丽克·奥布斯特·森德
沃尔特·维凡
托马斯·沃尔特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107683283A publication Critical patent/CN107683283A/zh
Application granted granted Critical
Publication of CN107683283B publication Critical patent/CN107683283B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680031828.0A 2015-08-12 2016-08-08 Bace1抑制剂 Expired - Fee Related CN107683283B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15180767.4 2015-08-12
EP15180767 2015-08-12
PCT/EP2016/068830 WO2017025491A1 (en) 2015-08-12 2016-08-08 Bace1 inhibitors

Publications (2)

Publication Number Publication Date
CN107683283A CN107683283A (zh) 2018-02-09
CN107683283B true CN107683283B (zh) 2021-05-18

Family

ID=53835951

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680031828.0A Expired - Fee Related CN107683283B (zh) 2015-08-12 2016-08-08 Bace1抑制剂

Country Status (5)

Country Link
US (2) US10246468B2 (enExample)
EP (1) EP3334742B1 (enExample)
JP (1) JP6895424B2 (enExample)
CN (1) CN107683283B (enExample)
WO (1) WO2017025491A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6895424B2 (ja) * 2015-08-12 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤
TWI905974B (zh) 2018-09-06 2025-11-21 日商第一三共股份有限公司 抗體藥物結合物之用途
CA3135276A1 (en) 2019-04-17 2020-10-22 Bard Access Systems, Inc. Catheter securement device including extended anchor pad and release liner clasping features
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174781A1 (en) * 2012-05-24 2013-11-28 F. Hoffmann-La Roche Ag 5-amino[1,4]thiazines as bace 1 inhibitors
WO2014114532A1 (en) * 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Fluoro-[1,3]oxazines as bace1 inhibitors
WO2014150331A1 (en) * 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140054295A (ko) * 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
EP2852596B1 (en) * 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Thienopyrimidines
EP3083644B1 (en) * 2013-12-20 2019-03-13 F.Hoffmann-La Roche Ag 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines
EP3172206B1 (en) * 2014-07-25 2019-01-30 F.Hoffmann-La Roche Ag Pyridyl-triazabicycles
WO2016055496A1 (en) * 2014-10-10 2016-04-14 F. Hoffmann-La Roche Ag Bace1 inhibitors
WO2016071211A1 (en) * 2014-11-03 2016-05-12 F. Hoffmann-La Roche Ag Bace1 inhibitors
JP6895424B2 (ja) * 2015-08-12 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174781A1 (en) * 2012-05-24 2013-11-28 F. Hoffmann-La Roche Ag 5-amino[1,4]thiazines as bace 1 inhibitors
WO2014114532A1 (en) * 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Fluoro-[1,3]oxazines as bace1 inhibitors
WO2014150331A1 (en) * 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use

Also Published As

Publication number Publication date
CN107683283A (zh) 2018-02-09
US10246468B2 (en) 2019-04-02
EP3334742A1 (en) 2018-06-20
US20190270757A1 (en) 2019-09-05
US10696691B2 (en) 2020-06-30
US20190002476A1 (en) 2019-01-03
JP6895424B2 (ja) 2021-06-30
WO2017025491A1 (en) 2017-02-16
JP2018522915A (ja) 2018-08-16
EP3334742B1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
CN113286794A (zh) Kras突变蛋白抑制剂
US10696691B2 (en) BACE1 inhibitors
JP2020509004A (ja) Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
KR20100055456A (ko) 다환식 화합물
CN102372698A (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
AU2010297263A1 (en) Substituted N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amines
CN105283457A (zh) 作为β-分泌酶(BACE)抑制剂的4-氨基-6-苯基-5,6-二氢咪唑并[1,5-A]吡嗪衍生物
WO2020117877A1 (en) Compounds, compositions and methods of use
US20190352312A1 (en) Pyridyl-triazabicycles
JP6554547B2 (ja) Ｂａｃｅ１阻害剤
US9540397B2 (en) BACE1 inhibitors
US20250213558A1 (en) T-type calcium channel modulators comprising a piperazine or 1,4-diazepane core and methods of use thereof
HK1249516A1 (en) Bace1 inhibitors
HK1249516B (zh) Bace1抑制剂
CN107108657A (zh) N‑[3‑[(4aR,7aS)‑2‑氨基‑6‑(5‑氟嘧啶‑2‑基)‑4,4A,5,7‑四氢吡咯并[3,4‑D][1,3]噻嗪‑7a‑基]‑4‑氟‑苯基]‑5‑甲氧基‑吡嗪‑2‑甲酰胺的甲苯磺酸盐
HK1233249A1 (en) Bace1 inhibitors
JP2025018434A (ja) Ｍｍｐ９阻害作用を有するインドール化合物
HK1233249B (zh) Bace1抑制剂
CN101238111A (zh) 用于治疗阿尔茨海默氏病的环缩酮β-分泌酶抑制剂
HK1238238A1 (en) Bace1 inhibitors
HK1238238B (zh) Bace1抑制剂
HK1230195A1 (en) 2,2,2-trifluoroethyl-thiadiazines
HK1232868A1 (en) Pyridyl-triazabicycles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1249516

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210518